Inflammatory bowel disease diagnostic method, diagnostic probe and diagnostic kit

By measuring the amount of anti-EPCR antibodies and using EPCR as a diagnostic probe and kit, the specificity problem of inflammatory bowel disease diagnosis in the existing technology is solved, and accurate diagnosis and risk assessment of inflammatory bowel disease are achieved.

CN114270191BActive Publication Date: 2025-09-16TOHOKU UNIV
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202080056815.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-08-29
Filing Date
2020-08-25
Publication Date
2025-09-16
Estimated Expiration
2040-08-25

AI Technical Summary

Technical Problem

Existing technologies have difficulty in specifically detecting or diagnosing inflammatory bowel diseases, especially ulcerative colitis and Crohn's disease, and the positive rate of diagnostic markers is low.

Method used

By measuring the amount of anti-endothelial cell protein C receptor antibodies (anti-EPCR antibodies) in the subject's sample and using EPCR as a diagnostic probe and kit, specific diagnosis of inflammatory bowel disease can be achieved.

Benefits of technology

It can specifically diagnose inflammatory bowel disease, including determining the disease status, risk, severity, treatment effect and recurrence, improving the accuracy and reliability of diagnosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114270191B_ABST
    Figure CN114270191B_ABST
Patent Text Reader

Abstract

The present application provides a novel determination method, diagnostic probe, and diagnostic kit for inflammatory bowel disease. The method for determining whether a subject has inflammatory bowel disease comprises measuring anti-endothelial cell protein C receptor antibodies (anti-EPCR antibodies) in a sample collected from a subject.
Need to check novelty before this filing date? Find Prior Art

Claims

1. Use of endothelial cell protein C receptor (EPCR) in the manufacture of a probe or kit for determining inflammatory bowel disease, wherein the method for determining inflammatory bowel disease comprises measuring anti-endothelial cell protein C receptor (EPCR) antibodies in a sample collected from a subject, wherein the inflammatory bowel disease is ulcerative colitis.

2. The method according to claim 1, comprising: contacting the sample collected from the subject with endothelial cell protein C receptor (EPCR), measuring the amount of the anti-endothelial cell protein C receptor antibody, i.e., anti-EPCR antibody, in the sample, and When the measured value is higher than the reference value, the subject is determined to have inflammatory bowel disease.

3. The use according to claim 1 or 2, wherein The determination is to determine whether the patient has inflammatory bowel disease.

4. The use according to claim 1 or 2, wherein The sample is blood, serum or plasma.

Citation Information

Patent Citations

  • Carrier unit and elevator

    JP2019156558A